According to Vision Research Reports, the global cancer gene therapy market size was valued at USD 1.9 billion in 2021 and is expected to reach around USD 5.4 billion by 2030, poised to grow at a 10.1% CAGR over the forecast period 2022 to 2030.
According to Vision Research Reports, the global cancer gene therapy market size was valued at USD 1.9 billion in 2021 and is expected to reach around USD 5.4 billion by 2030, poised to grow at a 10.1% CAGR over the forecast period 2022 to 2030.
Cancer gene therapy has gained popularity in the last few years due to its high success rates during clinical and preclinical trials. The emerging field delivers a number of potential applications for cancer treatments. It offers various advances in the field of molecular biology, molecular genetics, immunology, virology, and molecular genetics. In various instances, this technique for cancer has been intended to augment existing therapies, such as immunotherapies and chemotherapies.
The cancer gene therapy approaches include oncolytic virotherapy, immunotherapy, and gene transfer. It can be utilized in different ways. For instance, altering gene regulation, replacing defective and missing genes with healthy genes, and introducing foreign genes into cells to change their function. The most common method is to replace a cancer-causing mutant gene with a healthy one.
Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/39503
Viral and non-viral vector products are needed for this technique. Non-viral vectors are normally utilized to transfer the different types of nucleic acids such as large DNA molecules ((Plasmid DNA: p DNA), small DNA, and RNA (m RNA, Si RNA, Ribozymes). Moreover, viral-vector therapies use modified viruses as drug-delivery vehicles to insert specific DNA sequences- regulatory RNAs (e.g. siRNAs), encoding genes, or other therapeutic substrates into cells.
Key Takeaways:
- Based on therapy, the oncolytic virotherapy segment accounted for about 49.3% of the total market share in 2021.
- In terms of indication, sales in the breast cancer segment are forecast to grow at a CAGR of 9.7% in the forecast period.
- By service provider, demand in the hospitals segment will grow at a 9.3% CAGR through 2032.
- The U.S. will dominate the North America cancer gene therapy market over the forecast period.
- China will emerge as a lucrative pocket, accounting for 32.3% of the East Asia cancer gene therapy market share over the assessment period.
- Demand in Germany is expected to increase at a 11.9% CAGR over the assessment period.
Despite the slow clinical progress, researchers are undertaking efforts to develop specific non-toxic cancer therapies that are rising exponentially. As of now, more than 500 products under trial have been listed with the FDA. There is a number of strategies currently being followed during the cancer treatments. For instance,
- Minimize cancerous cell proliferation and rise cell cycle control by restoring functions such as RB and p53
- Rise in immunological rejection of tumor by the host
The pipeline for cancer therapies is quite strong and various companies are engaged in developing efficient products. Small biopharma companies are also emerging in the cell and gene therapy industry. For instance, Autolus Therapeutics is developing AAV-based gene therapies. The company is targeting patients suffering from chronic, systemic diseases using this technique.
Moreover, improving the regulatory scenario is also expected to increase the product launch in the market. For instance, in March 2021, Bluebird Bio and Bristol Myers Squibb received FDA approval for Abecma (idecabtagene vicleucel). It is a cell-based gene therapy to treat patients with multiple myeloma.
In addition, in February 2022, the University of Pennsylvania doctors’ team announced that cancer patients treated with gene therapy in 2010 shows no sign of cancer in the body. The two examples demonstrate how the therapy, known as CAR-T cell therapy, can fight cancer right away inside the body, and evolve to battle against the tumor. Moreover, in July 2022, ImmunoACT, backed by Laurus Labs, announced that it tested a novel gene therapy cure for leukemia and lymphoma. The lab is working with CD19 CAR-T Cell for leukemia and lymphoma. According to the lab, findings begin to appear after about a week.
Which Cancer Gene Therapy is Driving the Market?
“Demand for Oncolytic Virotherapy Will Gain Traction”
Based on therapy, the oncolytic virotherapy accounted for about 49.3% of the total market share in 2021. Sales in this segment are expected to increase at a 9.5% CAGR over the forecast period.
Oncolytic virus therapy is a promising new therapeutic approach for cancer treatment that has recently been identified. An oncolytic virus is a genetically designed or naturally occurring virus that may selectively reproduce in cancer cells and kill them while causing no harm to normal tissues. Oncolytic virus therapy differs from gene therapy in that it exploits the virus as an active pharmacological reagent rather than just a carrier for transgene delivery.
Which Indication Category is Leading the Cancer Gene Therapy Market?
“Sales of Cancer Gene Therapy for Breast Cancer to Remain High”
In terms of indication, the breast cancer segment held about 24.5% of the total market share in 2021, and is expected to expand at a 9.7% CAGR over the forecast period. Various governments in underdeveloped nations are taking steps to stimulate research efforts aimed at producing cancer gene therapy and treatment plans to lower mortality and morbidity rates, which will drive growth in the cancer gene therapy market over the forecast period.
Which Service Provider Benefits the Most in the Cancer Gene Therapy Market?
“Adoption of Cancer Gene Therapy in Hospitals Will Increase”
By service provider, the hospitals segment will expand at a 9.3% CAGR over the assessment period. The presence of trained providers, as well as institutional facilities equipped with treatment options are some factors expected to drive sales in this segment in the forthcoming years.
Moreover, the availability of reimbursement plans for gene therapy will continue pushing sales over the forecast period.
Key Players
- Abeona Therapeutics
- Asklepios BioPharmaceutical
- Celgene
- Elevate Bio
- GlaxoSmithKline
- Bluebird bio
- Genelux Corporation
- OncoGenex Pharmaceuticals
- Introgen Therapeutics
- Altor Bioscience
- Merck
- GenVec
- BioCancell
Market Segmentation
- By Therapy
- Oncolytic Virotherapy
- Gene-induced Immunotherapy
- Gene Transfer
- By End-user
- Research Institutes
- Biopharma Companies
- Diagnostic Centres
- Others
- By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Click Here to View Full Report Table of Contents
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/39503
You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333